Nitta Gelatin India Ltd
Incorporated in 1975, Nitta Gelatin India Ltd manufactures and sells ossein, gelatin, and collagen peptide[1]
- Market Cap ₹ 743 Cr.
- Current Price ₹ 818
- High / Low ₹ 1,184 / 745
- Stock P/E 10.4
- Book Value ₹ 384
- Dividend Yield 0.73 %
- ROCE 36.6 %
- ROE 29.7 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 102% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 25.3%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
303 | 287 | 355 | 357 | 341 | 343 | 261 | 294 | 354 | 429 | 487 | 473 | 497 | |
263 | 277 | 329 | 318 | 304 | 316 | 243 | 268 | 314 | 378 | 397 | 363 | 395 | |
Operating Profit | 40 | 10 | 27 | 39 | 37 | 27 | 18 | 27 | 40 | 51 | 90 | 110 | 102 |
OPM % | 13% | 3% | 8% | 11% | 11% | 8% | 7% | 9% | 11% | 12% | 18% | 23% | 20% |
2 | 0 | 2 | 2 | 9 | 5 | 1 | 3 | 5 | 6 | 5 | 17 | 12 | |
Interest | 7 | 6 | 8 | 6 | 4 | 7 | 8 | 8 | 5 | 5 | 4 | 3 | 3 |
Depreciation | 10 | 11 | 10 | 9 | 10 | 14 | 14 | 15 | 15 | 14 | 13 | 14 | 14 |
Profit before tax | 26 | -7 | 10 | 26 | 32 | 11 | -4 | 7 | 24 | 38 | 78 | 110 | 97 |
Tax % | 40% | -32% | 49% | 37% | 36% | 65% | -28% | -15% | 26% | 29% | 25% | 25% | |
16 | -5 | 5 | 17 | 20 | 4 | -3 | 8 | 18 | 27 | 59 | 82 | 72 | |
EPS in Rs | 13.91 | -5.46 | 5.62 | 18.38 | 22.57 | 4.16 | -2.91 | 8.70 | 19.72 | 29.30 | 64.72 | 90.86 | 78.93 |
Dividend Payout % | 22% | 0% | 18% | 14% | 11% | 60% | -52% | 29% | 15% | 14% | 12% | 7% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 13% |
3 Years: | 10% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 34% |
5 Years: | 102% |
3 Years: | 66% |
TTM: | -15% |
Stock Price CAGR | |
---|---|
10 Years: | 17% |
5 Years: | 44% |
3 Years: | 53% |
1 Year: | 3% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 20% |
3 Years: | 25% |
Last Year: | 30% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
Reserves | 111 | 106 | 113 | 125 | 130 | 138 | 133 | 134 | 154 | 176 | 231 | 307 | 340 |
42 | 53 | 53 | 70 | 84 | 104 | 101 | 79 | 75 | 80 | 33 | 27 | 32 | |
41 | 42 | 40 | 45 | 48 | 55 | 51 | 53 | 49 | 51 | 53 | 57 | 54 | |
Total Liabilities | 202 | 210 | 214 | 249 | 271 | 305 | 295 | 276 | 287 | 316 | 326 | 400 | 435 |
68 | 82 | 77 | 80 | 77 | 110 | 126 | 116 | 108 | 102 | 109 | 106 | 104 | |
CWIP | 8 | 8 | 8 | 7 | 11 | 10 | 3 | 4 | 2 | 7 | 7 | 8 | 9 |
Investments | 32 | 32 | 32 | 45 | 27 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 10 |
93 | 88 | 96 | 117 | 157 | 181 | 161 | 151 | 172 | 202 | 206 | 281 | 313 | |
Total Assets | 202 | 210 | 214 | 249 | 271 | 305 | 295 | 276 | 287 | 316 | 326 | 400 | 435 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
16 | 23 | 17 | 29 | 11 | 26 | 28 | 33 | 15 | 13 | 78 | 79 | |
-11 | -24 | -8 | -22 | -3 | -7 | -13 | -7 | -3 | -11 | -15 | -44 | |
-4 | 0 | -8 | 11 | -6 | -20 | -14 | -29 | -12 | -2 | -53 | -15 | |
Net Cash Flow | -0 | -0 | 1 | 18 | 2 | -0 | 1 | -3 | -0 | -1 | 10 | 20 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 31 | 28 | 23 | 21 | 56 | 65 | 74 | 34 | 57 | 65 | 59 | 60 |
Inventory Days | 138 | 129 | 99 | 112 | 127 | 151 | 202 | 220 | 161 | 148 | 133 | 164 |
Days Payable | 55 | 80 | 50 | 43 | 37 | 56 | 67 | 58 | 46 | 30 | 45 | 53 |
Cash Conversion Cycle | 114 | 77 | 72 | 90 | 147 | 160 | 210 | 196 | 172 | 182 | 148 | 171 |
Working Capital Days | 69 | 61 | 61 | 59 | 101 | 92 | 103 | 72 | 103 | 114 | 92 | 100 |
ROCE % | 22% | -1% | 11% | 17% | 17% | 7% | 2% | 6% | 13% | 17% | 31% | 37% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 13 Nov
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Nov - Copies of Newspaper Advertisements published in English and Malayalam Newspapers, pertaining to the Un-audited financial results of the Company for the Quarter and Half year …
-
Board Meeting Outcome for Outcome Of Board Meeting- Quarterly And Half Yearly Financial Results For The Period Ended 30Th September 2024
8 Nov - Un-audited financial results for Q2 and H1 2024.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
29 Oct - Intimation of loss of share certificates and issuance of duplicates.
-
Board Meeting Intimation for Considering And Approving Inter Alia The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended 30Th September 2024
25 Oct - Board meeting scheduled for financial results approval.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
NGIL, a joint venture between the Kerala State Industrial Development Corporation (32% shareholding) and Osaka-based NGI (43% stake), manufactures gelatin, ossein, limed ossein, and DCP from processed animal bones. It also produces collagen peptide-based consumer products for the pharmaceutical and healthcare industries.